Inscopix Showcases New Products and Key Scientific Presentations from Customers at the 52nd Annual Meeting of the Society for Neuroscience

Highlights include a behavioral synchronization system, the expansion of the cloud-based IDEAS Platform for individual lab use and novel results from the company’s first Alzheimer’s Disease assay

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Inscopix, a neuroscience company helping decode the brain for tomorrow’s treatments, will be showcasing the latest innovations around its brain imaging platform for novel neuroscience research and celebrating the successes of its customers at the 52nd annual meeting of the Society for Neuroscience (SfN), to be held in San Diego, November 12-16.

With an unprecedented number of more than 60 research publications from customers expected to be displayed at the conference, Inscopix will be showcasing how its new platform technologies are the centerpiece of next-generation neuroscience labs.

“Every day, researchers around the world are using Inscopix’s technology to break new ground in understanding how the brain works. This year’s Neuroscience meeting will be an opportunity for us to celebrate, in person, their accomplishments and demonstrate our long-term vision of bridging technologies and integrating modalities to create the Neuroscience Lab of the Future,” said Kunal Ghosh, Ph.D., founder and CEO of Inscopix. “Our products are powering research into brain function and dysfunction, and we are excited to showcase the work of our customers and collaborators, and unveil new products to build on our customers’ successes – including IDEAS, an industry-first, cloud-based software for Neuroscience data management and analysis.”

New Product Innovations for the Inscopix Community

The Inscopix SfN Booth #1028 will highlight two key 2022 additions to the company’s miniscope platform and applications portfolio.

• The launch of the nVision™ System enables acquisition of behavioral data and one step synchronization between calcium imaging and free behavior movies.
• The release of the Inscopix Data Exploration, Analysis and Sharing (IDEAS) Platform to the individual lab builds upon the July 2022 enterprise launch, and allows academic researchers to utilize the first-of-its-kind, cloud-based solution to managing and analyzing big brain data at scale.

Together, these new product introductions will not only help researchers gain deeper neural circuit insights in function and behavior, but to do so more efficiently, collaboratively and scalably than ever before. The Inscopix booth will have scheduled demonstrations of the IDEAS Platform, sign-ups for which are currently open here. The nVision System will be on display at the booth for the first time, along with the company’s flagship dual-color imaging nVue™ System and core imaging and optogenetics capabilities in the nVista™ System and nVoke™ System, respectively. The company is also offering the opportunity to book a 1:1 consultation here with the company’s expert scientists to see any and all of the products and applications in person while at the meeting.

Inscopix Showcases New Alzheimer’s Disease Assay

Two abstracts will be presented by Inscopix scientists, showcasing the new and powerful dynamic blood flow imaging application, and an overview of the company’s first foray into developing a highly sensitive and translationally relevant Alzheimer’s Disease assay using the miniscope imaging platform.

“Alzheimer’s disease is devastating and the leading neurodegenerative disease in the U.S., affecting more than 6 million individuals and their families and friends. With the hope of catalyzing the discovery of safer and more effective precision neurotherapeutics for Alzheimer’s, we are validating a new kind of neurocircuitry-based imaging assay which will enable unprecedented access to early-stage, disease-driven functional changes associated with this debilitating disease,” said David Gray, CSO of Inscopix.

• Tools for acquisition and analysis of simultaneous neural activity and vascular dynamics in freely behaving animals
  • D. Ollerenshaw et al., Ph.D.
  • Session 577 - Optical Methodology: Application
  • Nov. 15, 2022, 1:00 PM - 2:00 PM (PST)
    
• Prefrontal cortex neuronal hyperactivity in a mouse model of Alzheimer’s beta-amyloidosis
  • S. Huang et al., Ph.D.
  • Session 120 - Alzheimer's Disease: Biomarkers II
  • Nov. 13, 2022, 9:00 AM - 10:00 AM (PST)

Celebrating the Successes of Inscopix’s User Community

The Inscopix user community is developing the most impressive research in neuroscience and expected to have a strong presence at the four-day meeting, with more than 60 poster presentations and five Special Lectures announced in the Program so far. The company’s popular annual SfN Tech Awards invited nearly 40 submissions in 2022, and three impactful abstracts have been awarded cash prizes for their innovative use of the Inscopix platform:

• Impaired feedforward inhibition of corticopontine neurons drives placebo analgesia
  • C. Cheng et al., Ph.D.
  • Session 048 - Pain Central Mechanisms
  • Nov. 12, 2022, 4:00 PM - 5:00 PM (PST)
    
• Accumbens Ca2+ Dynamics Underlying Natural Reward Seeking Behavior
  • R. Chalhoub et al.
  • Session 312 - Neural Basis of Reward I
  • Nov. 14, 2022, 8:00 AM - 9:00 PAM (PST)
    
• Neural Activity of the Locus Coeruleus-Medial Prefrontal Cortex Circuit During Sustained Attention
  • S. S. Adiraju et al.
  • Session 233 - Mechanisms of Attention: Rodent Models
  • Nov. 13, 2022, 2:00 PM - 3:00 PM (PST)

Inscopix will provide details of additional abstracts throughout the annual meeting via its corporate Twitter account (@Inscopix). Feel free to celebrate your successes by using the #InscopixSfN22 hashtag.

Meeting attendees can visit Inscopix Booth #1028 for a keepsake bound-copy of all research published at SfN using Inscopix technology, or email [e-mail] to schedule a conversation with a member of the company and get your copy.

About Inscopix, Inc.

Inscopix is a brain imaging platform company focused on decoding the mind to better understand and address all neurological disorders. We are solving perhaps the greatest unmet need in humanity – understanding how the brain works – and leveraging that knowledge to develop effective neurological treatments. With almost 200 peer-reviewed publications validating our innovative brain circuitry imaging technology, Inscopix is empowering the neuroscience research community to advance science while bringing a new generation of transformational therapeutics to patients with difficult-to-treat brain disorders. Learn more at inscopix.com and follow us @inscopix.